Hikma Highlights Long-Term Importance Of Biosimilars

CEO Siggi Olafsson Discusses The Evolution Of Hikma’s Injectables Business

Playing in biosimilars is essential for firms that want to lead in the sterile injectables space, Hikma CEO Siggi Olafsson commented as he discussed how the firm’s injectables business was expected to evolve over the coming years.

Timeline years 2025 blue pin
Hikma sees biosimilars becoming a significant part of its business from 2025 • Source: Olivier Le Moal / Alamy Stock Photo

Entering the biosimilars market is essential in the long-term for any company that wishes to be a leader in the sterile injectables space, Hikma CEO Siggi Olafsson commented as he discussed the evolution of the firm’s injectables business at the recent J.P. Morgan Healthcare conference.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Products